Is there a role for VeriStrat testing in determining when to use an EGFR TKI in previously treated squamous cell NSCLC?
Although PD-1 inhibitors are now standard of care for second-line therapy of advanced NSCLC, there remains the question of which therapy is best to use after failure of nivolumab or pembrolizumab. LUX-Lung 8 (http://www.ncbi.nlm.nih.gov/pubmed/26156651) recently demonstrated a survival advantage for afatinib over erlotinib in previously treated advanced squamous-cell NSCLC. Would the results of VeriStrat testing influence you to choose an EGFR TKI over chemotherapy in this setting?
Answer from: Medical Oncologist at Academic Institution
Excellent question and one that we have very little data to answer. Extrapolating from the second line PROSE trial (http://www.ncbi.nlm.nih.gov/pubmed/24831979), it seems reasonable to consider this test to help choose between TKI vs. chemotherapy as a third line option. That said, there are certain...
Sign in or Register to read more